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1. Introduction
Many of the recent advances in autism research that have provided fundamental insight
into this condition have come from the application of genetic/genomic approaches; these
advances have been fomented by the advent  of  new technologies  to  interrogate  the en‐
tire genome, such as array comparative genomic hybridization (aCGH), single nucleotide
polymorphism  (SNP)  microarrays,  transcriptome  sequencing,  and  whole  genome  or
whole exome sequencing (WGS/WES) [1]. With the recent advancement of these technol‐
ogies  over  more  traditional,  lower-resolution  technologies  such  as  cytogenetic  analysis,
came the ability to interrogate the entire genome at a high-resolution. With the improve‐
ment  of  next-generation  sequencing  technology,  as  well  as  the  reduction  in  the  cost  of
this  technique,  WGS  is  becoming  more  commonplace  in  the  search  for  novel  disease-
causing  variants  in  individual  patients.  Alternatively,  many  studies  have  utilized  WES,
as it  is less costly than sequencing the entire genome and coding simple nucleotide var‐
iants (SNVs) can often be more readily interpreted given knowledge provided by the ge‐
netic code. While the reduced cost and more readily interpretable variation have proven
to  be  distinct  advantages  of  this  method  over  whole-genome  sequencing,  it  is  well
known that many other variants in non-coding or regulatory regions can be pathogenic,
and  they  typically  cannot  be  discerned  by  whole-exome  sequencing,  which  requires  a
targeted-capture step to enrich for and focus analysis on the coding sequences of all an‐
notated protein-coding genes [2, 3]. Furthermore, repetitive or G-C rich regions or highly
homologous sequences are often excluded by WES, and copy number variations (CNVs)
usually  cannot  be  accurately  called  due  to  the  use  of  PCR-based  sample  preparation
methods. Nonetheless, the utility of WGS/WES in individual patient diagnosis and man‐
agement has been demonstrated by several recent reports [4-6].
© 2013 Lacaria and Lupski; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Some of the first studies providing a high-resolution view of the entire genome have re‐
vealed that a large number of CNVs are present in the genomes of healthy individuals, and
that CNVs account for a greater proportion of the nucleotide variation between two given
individual genomes than can be attributed to SNVs [7-9]. These structural alterations can
reach up to several megabases in length, but a much higher frequency is observed for small‐
er (<1 kb) CNVs [2]. And, as one would expect, the likelihood of CNVs becoming pathogenic
rises when they have an increased size and/or occur in gene-dense regions of the genome
[8]. Traditionally, structural variation (CNV) was not considered to play a causative role in
autism or ASD. However, recent studies have revealed that not only single-gene alterations,
but also CNVs can lead to autism or ASD. In fact, it is now becoming increasingly evident
that CNVs account for a larger proportion of new autism diagnoses than single-gene disor‐
ders. Recurrent CNVs at specific genomic loci have been associated with autism, including
15q11-q13, 16p11.2, 17p11.2, 22q13.3, 7q11.23, and 2q37, among others [1, 10-16]. While sev‐
eral of these loci are associated with known Centers for Mendelian Genomics, numerous
CNVs have also been observed in idiopathic autism, underscoring the importance of these
structural variations in the future of all types of autism research [17].
The application of next-generation sequencing technology to evaluate CNVs has also re‐
cently  been  described in  a  report  that  utilized whole-transcriptome sequencing  analysis
of  the  genomes of  a  cohort  of  patients  with  autism spectrum disorder  (ASD) [18].  This
approach allows for the evaluation of CNVs and overcomes some of the problems asso‐
ciated  with  CNV-calling  in  WES.  With  several  large-scale  projects  currently  underway,
the future of next-generation sequencing and whole-genome analysis in the study of au‐
tism  will  most  definitely  provide  many  new  insights  into  the  etiology  of  this  disease.
Currently,  Autism Speaks  is  working  in  collaboration  with  the  company BGI  to  gener‐
ate  the  largest  database  of  sequenced  genomes  of  individuals  with  ASD,  a  project
known as the “Autism Genome 10K.” Similarly,  the National Institute of Mental  Health
in  the  US  has  funded  another  large-scale  “Autism  Genome  Project.”  Mendelian/
syndromic  forms  of  autism are  also  currently  being  studied  by  the  Genomic  Disorders
consortium in the US by WES.
Among the  variants  identified in  the  large-scale  studies  of  patients  with  autism report‐
ed  to  date,  many  gene  networks/pathways  have  been  implicated,  including  genes  for
neuronal  adhesion  [18,  19],  ubiquitin  degradation  [19],  chromatin  remodelling  [5,  20],
sodium channels [13],  proteolysis [21],  cytoskeletal  organization [21],  signal transduction
[18],  neuropeptide  signalling  [18],  neurogenesis/synaptogenesis  [18],  neuronal  migration
[22],  basic  metabolism,  and  RNA  splicing  [22],  among  others.  While  these  pathways
may  seem  diverse,  repeated  “hits”  in  these  networks  support  the  “many  genes,  com‐
mon  pathway”  hypothesis  [22].  Importantly,  although  the  biological  function  of  ASD
susceptibility  genes  identified  via  these  whole-genome  studies  do  not  appear  to  lie
within the same network,  they likely converge to disrupt neuronal function in brain re‐
gions that  support  language,  social  cognition,  and behavioral  flexibility,  resulting in the
phenotypes commonly associated with ASD [22].
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2. Chromosome engineering mouse models for ASD
Since ASD is known to be a highly heterogeneous disorder with both genetic and environmen‐
tal components, modeling the disease in rodents, where environmental and background ef‐
fects  can  be  largely  controlled  and  systematically  manipulated  and  studied,  is  of  great
advantage in the study of the pathomechanisms underpinning autism. Furthermore, numer‐
ous tools for genetic manipulation and for behavioral analysis that are currently available and
developed for genetic studies in rodents can be leveraged to facilitate this avenue of research.
Importantly, behavioral assays have been developed and validated to objectively quantify the
phenotypes relative to autism, including both core and associated autistic-like phenotypes,
such as abnormal social behavior, communication deficits, and repetitive behaviors, as well as
autism-associated anxiety-like behaviors, motor defects, learning and memory deficits, sleep
disorders, sensory hypersensitivity, and seizures, among others [23] (Table 1; adapted from
Crawley et al, where a full description of these behavioral tests can be found; [23]).
With the importance of CNVs in the etiology of ASD established, chromosome-engineered
mouse models were then generated for the study of autism or ASD. The first such mouse
strains were developed over a decade ago using a chromosome-engineering approach [24].
This technique allows for the creation of a targeted duplication or deletion in the desired lo‐
cation by first generating the rearrangement in mouse embryonic stem (ES) cells which can
then be established as mouse strains via Cre/loxP site-specific recombination [25, 26]. To gen‐
erate the desired rearrangement, two gene-targeting steps are required to prepare each end
point for a selectable recombination event (Figure 1). Importantly, the type of rearrangement
(deletion, duplication, inversion) depends on the relative orientation of the loxP sites; if the
sites are in the same orientation, the region between them can be deleted or duplicated, but
if they are in opposite orientation, an inversion results [25]. The cis or trans configuration is
also relevant; trans insertion (insertion in each chromosome homologue) of loxP sites ena‐
bles generation of both deletion and duplication in the same ES cells. Transient transfection
of the ES cells with a vector expressing Cre recombinase facilitates the recombination be‐
tween the targeted loxP sites, and cells containing the event can be selected for using hypo‐
xanthine aminopterin thymidine (HAT)-containing media due to the reconstitution of a
functional Hprt cassette as a result of the recombination [25]. The resulting mouse models
harbor either a chromosomal duplication or deletion of a defined region that is syntenic to
the copy number variable region in humans. Importantly, chromosome-engineered mouse
models are distinct from monogenic animal models in that they harbor structural chromoso‐
mal rearrangements resulting in specific, targeted CNVs with genomic intervals that may
span several megabases and contain numerous genes, many of which may be of unknown
function. In contrast, monogenic animal models primarily utilize a reverse-genetics ap‐
proach to knock-out or transgenically-overexpress the specific single gene of interest, limit‐
ing the study to that one particular gene. A publicly-available resource can facilitate
chromosome engineering for the targeted manipulation of the mouse genome; the mutagen‐
ic insertion and chromosome engineering resource (MICER) can be utilized to access vectors
to create chromosomal rearrangements or to study gene disruptions in a high-throughput
manner [27]. (http://www.sanger.ac.uk/resources/mouse/micer/).
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Core features of autism Analogous feature/assay in mice
Abnormal social interactions Preference for social novelty
Social recognition
Home cage monitoring - nesting patterns
Direct social interactions / juvenile play
Social approach to a stranger mouse
Impaired social communication Vocalizations during direct social interaction
Parental retrieval of separated pups
Ultrasonic vocalizations by separated pups
Response to olfactory cues
Repetitive or restrictive behavior Perseverative holeboard exploration
Behavioral stereotypies/ home cage observation
Reversal of a position habit in maze tasks
Marble burying
Novel object exploration
ASD- Associated features Analogous feature/assay in mice
Anxiety Elevated plus maze
Light/dark exploration
Open field analysis
Theory of mind deficits Social transmission of food preference
Avoidance of aggressive encounters
Intellectual disability Morris water maze
Contextual and cued fear conditioning
T-maze
Motor defects Rotarod test for motor learning
Wire hang
Dowel walking
Footprint analysis
Aggression Resident intruder attack
Tube test for social dominance
Sleep disturbances Circadian running wheel
Home cage monitoring - activity levels
Hypersensitivity to sensory stimuli Pre-pulse inhibition
Acoustic startle
Hot plate test for nociception
Seizures Sensitivity to audiogenic or drug-induced seizures
Table 1. Behavioral tests for the evaluation of autistic-like features in mice
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Figure 1. Generating defined chromosome rearrangements. Defined endpoints of the desired interval for rear‐
rangement (A and B) are modified by gene targeting in embryonic stem (ES) cells to allow for introduction of a loxP
site (blue triangle), a non-functional portion of the HPRT cassette [5’ or 3’), and a positive selectable marker (Neo or
Puro). The targeted ES cells are then transiently transfected with a vector expressing Cre recombinase, which facilitates
recombination between the loxP sites, resulting in either deletion (Df) or duplication (Dp) of the intervening region. In
this example, reconstitution of the Hprt cassette via recombination between loxP sites lying in a shared intron be‐
tween the two halves confers resistance to hypoxanthine aminopterin thymidine (HAT), which can be used to select
for the deletion event. Two positive selectable markers (Puro and Neo) identify the duplication event. A full explana‐
tion of this technology and more examples of chromosome recombineering are outlined by Mills et al [25].
We will discuss specific examples of chromosome-engineered mouse models of ASD for
which the neurobehavioral phenotypes have been described using established rodent be‐
havioral assays, including mice harboring duplication or deletion of the genomic interval
syntenic to human chromosome 16p11.2, 15q11-q13, and 17p11.2, which all model CNVs
that have been identified in patient populations with autism [28-30]. Most of the CNV-based
animal models of ASD described to date have focused on syndromic forms of autism, as the
underlying genetic cause of these genomic disorders is often well-described.
By definition, genomic disorders result from structural changes in the genome, wherein the
genomic instability often reflects a susceptible genome architecture, that leads to disease
traits [31]. These structural rearrangements or CNVs commonly cause the disruption or
complete loss or gain of dosage-sensitive gene(s). Alternatively, CNVs can cause gene fu‐
sion, position effects, transvection effects, or the unmasking of a recessive allele or function‐
al polymorphism [32]. Genomic disorders are therefore distinct from traditional genetic
syndromes, which are typically caused by DNA sequence-based changes [33]. Within the
past decade, several technologies, including array comparative genomic hybridization
(aCGH), next-generation sequencing, and single nucleotide polymorphism (SNP) genotyp‐
Advances in Autism Research – The Genomic Basis of ASD
http://dx.doi.org/10.5772/53689
253
ing platforms, have been utilized to detect and analyze CNVs in the genome and to investi‐
gate the mechanism by which these CNVs are generated [34]. CNVs can be formed by
several mechanisms, such as non-allelic homologous recombination (NAHR), non-homolo‐
gous end joining (NHEJ), or fork stalling and template switching (FoSTeS) [35]. NAHR,
which is often mediated by low copy repeats (LCRs) with high (~95%) sequence similarity
flanking the rearranged region, is the most common mechanism by which recurrent CNVs
are created. Often this mechanism can result in recurrent genomic rearrangements that are
observed in multiple patients with the same disorder, as in Charcot-Marie-Tooth disease
type 1A, Prader-Willi syndrome, and Smith-Magenis Syndrome, among many others [32,
33]. The genomic architecture rendering genomic instability at three loci that are enriched
for LCRs are shown in Figure 2.
Figure 2. The genomic structure of loci associated with CNV-based ASD. (A) Chromosomes 15q11-13, (B)
16p11.2, and (C) 17p11.2, are enriched for LCRs, or segmental duplications (indicated by red arrows), which facilitate
non-allelic homologous recombination (NAHR), resulting in the generation of CNVs (blue and red bars). This figure
was generated using the genome browser provided by UCSC (http://genome.ucsc.edu/index.html?org=Hu‐
man&db=hg18&hgsid=289381925].
3. ASD associated with CNVs on chromosome 16p11.2
In recent years, whole genome analyses of cohorts of patients with autism have identified
recurrent CNVs on chromosome 16p11.2, effectively linking reciprocal microduplications
and microdeletions at this locus with increased susceptibility to ASD [12, 36-39]. Important‐
ly, further studies have revealed that CNVs at this locus are responsible for ~1% of all ASD
diagnoses, making it the most common CNV to be associated with ASD identified to date
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[13]. The 16p11.2 locus is flanked by two directly repeated segmental duplications of ~145
kb, which mediate the NAHR that results in the loss or gain of ~600 kb intermediate region
containing ~27 protein-coding genes [9, 12, 40].
Interestingly, the microduplication of this region has also been linked to schizophrenia, sug‐
gesting the presence of an underlying biological link between these two disorders [41, 42].
This phenomenon also gives a potential genetic basis for the hypothesis of Crespi et al,
which states that autism and schizophrenia represent diametric disorders of the social brain
[43]. Thus, schizophrenia and autism might reflect mirror traits of the opposing extremes of
behavioral phenotypes reflecting evolution of the social brain [43]. The phenotypes caused
by CNV at the 16p11.2 locus are extremely heterogeneous, and, in addition to ASD, they
have been reported to include metabolic disorders [44-47], cardiac anomalies [40, 48], de‐
pressive disorder [49], speech delay [50], mental retardation [40, 51, 52], vertebral anomalies
[52], syringomyelia [53], abnormal head size [36], and epilepsy [36, 40], as well as other vari‐
ous congenital anomalies and behavioral abnormalities [44]. As the phenotypes of many
more patients harboring CNVs in this genomic region are delineated, the full phenotypic
spectrum associated with this locus will likely become more well-defined, and the critical
genomic interval and dosage-sensitive genes responsible for the phenotypes will be deter‐
mined. Indeed, a more recent study described a patient pedigree for a family with multiple
generations of autism or ASD that also carry a smaller-sized deletion within the common
deletion of 16p11.2, thereby reducing the “critical” interval for ASD to a 118 kb region con‐
taining only 5 genes: MVP, CDIPT1, SEZ6L2, ASPHD1, and KCTD13 [54]. To date, none of
these genes have been significantly associated with an elevated risk for ASD, which indi‐
cates that the situation is likely much more complex [37, 55]. Furthermore, correlation be‐
tween the phenotypes of patients harboring different- or similar-sized CNVs is confounded
by extreme heterogeneity and variability of symptoms. For example, a family with three af‐
fected members harboring identical 16p11.2 deletions was recently described to have mini‐
mal symptom overlap between family members [56]. Subsequent studies have aimed at
using model organisms to identify the key dosage-sensitive genes within this region that
give rise to the abnormal phenotypes [29, 57, 58]. Among these, chromosome-engineered
mouse models harboring reciprocal deletion or duplication of the mouse chromosome syn‐
tenic to human chromosome 16p11.2 have been generated to study the physiological and be‐
havioral phenotypes associated with these chromosome abnormalities [29].
4. Animal models for human 16p11.2 CNVs
Mouse  models  were  generated  through  a  chromosome  engineering  approach  for  the
study of human 16p11.2 deletion and duplication CNVs [29].  It  was observed that ~50%
of mice harboring the deletion CNV die  shortly  after  birth,  while  duplication mice sur‐
vive to adulthood, suggesting that the deletion CNV results in a more severe phenotype
than  the  duplication  [29].  A  similar  phenomenon  has  been  observed  in  other  genomic
disorders caused by reciprocal  CNVs, including Smith-Magenis and Potocki-Lupski syn‐
dromes [15]. Expression of the genes within the 16p11.2 region corresponds to gene dos‐
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age in four brain regions that may be relevant for autism, including the olfactory bulbs,
cortex, cerebellum, and brainstem [29].
In-cage neurobehavioral phenotypes were assessed in these mice to determine what, if any,
affect these CNVs had on autistic-like behaviors. As expected, deletion mice displayed the
most abnormal phenotypes, while duplication mice had fewer and milder symptoms. Inter‐
estingly, reciprocal phenotypes were sometimes observed for mice harboring reciprocal
CNVs. For example, the amount of time spent resting in the cage was lower in deletion mice
but higher in duplication mice relative to controls, indicating that 16p11.2 CNVs affect the
rate and timing of specific behaviors in a dosage-dependent manner. Deletion mice dis‐
played an abnormal ceiling-climbing behavior where they demonstrated marked stereotypic
and nonprogressive motor behaviors, similar to what is often observed in patients with au‐
tism or patients with lateral hypothalamic and nigrostriatal lesions in the brain. These ab‐
normal behaviors were accompanied by volumetric and morphological changes in several
brain regions, including the lateral hypothalamus. Importantly, the difference between dele‐
tion mice and duplication mice was greater than that between deletion mice and controls,
indicating that these effects are reciprocal or opposing in nature.
No significant abnormal social behavior was observed in these animal models in the 3-
chamber test for sociability, indicating either that these animals do not display social abnor‐
malities, or that further investigation into the social behavior of these animals is required.
Indeed, with the subtle nature of many social interactions in rodents, it is quite possible that
social abnormalities exist in these mice but have not yet been described. It is also distinctly
possible that the ‘in-cage’ environment does not elicit a social deficit that might perhaps be
observed in the wild or natural environment of the animal. An extensive battery of tests for
social behavior will be required to rule out the possibility of further abnormalities.
Many of the genes mapped to the altered region have unknown function, and therefore,
unknown significance or contribution to the disease phenotype. In order to further delin‐
eate  the  function of  the  dosage-sensitive  genes  within  the  common duplication/deletion
region, zebrafish models were generated [57, 58]. The first study aimed to investigate the
diametric  head size  phenotypes  linked to  this  locus,  as  in  addition  to  ASD,  deletion  is
known to result in macrocephaly, and duplication gives rise to microcephaly [36, 57]. In
this study, zebrafish were utilized for an in vivo  overexpression screen, which identified
the gene KCTD13  as the likely candidate for the neurodevelopmental phenotypes associ‐
ated with CNVs at 16p11.2. Interestingly, this gene was also one of the 5 genes found in
a minimal critical deletion interval for ASD [54]. Overexpression of this gene in zebrafish
resulted in microcephaly,  while  the reciprocal  reduced expression of  this  locus by mor‐
pholino  oligonucelotides  resulted  in  macrocephaly,  thereby  mirroring  the  phenotypes
seen in humans harboring CNVs at this locus [57]. Further study revealed that the func‐
tion  of  this  gene  is  likely  conserved  across  species,  and  it  is  required  to  maintain  the
proliferative status of cortical  progenitor cells  in mice [57].  Furthermore,  this gene is  af‐
fected in a complex genomic rearrangement identified in a patient with autism [57]. Tak‐
en together, these results indicate that KCTD13  is a likely candidate for further study of
the neurological phenotypes associated with CNV at this locus.
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Another study was able to identify homologs of 21 of the known 16p11.2 human genes in
the zebrafish genome by family tree comparisons [58]. These genes were then targeted for
loss of function studies by injecting antisense morpholino oligonucleotides into early em‐
bryos [58]. Interestingly ~79% of the genes tested by this method were required for proper
brain, eye, or nervous system development, and two of the genes were determined to be
dosage-sensitive, with abnormal phenotypes present with a ~50% reduction in gene expres‐
sion [58]. The results of this study suggest that at least two genes, aldolase a (aldoaa) and ki‐
nesin family member 22 (kif22), are highly dosage-sensitive and are required for proper
brain function, making them likely candidates for future studies of the ASD associated with
CNV of this region [58].
These two studies indicate that while kctd13, kif22, and aldoaa are all potentially interesting
dosage-sensitive candidate genes, further investigation is needed to determine whether
these genes act together in a epistatic manner to contribute to the full neurological pheno‐
type, whether they modify each other via cis interactions, or whether other genes or genetic
elements in the 16p11.2 locus are also contributing to the phenotype. The current data,
which could not have been obtained without these important studies in model organisms,
cannot distinguish between these possibilities, but they provide a starting point for research
into the function of these genes and the molecular pathways underpinning the phenotypes
associated with 16p11.2 CNVs.
5. Prader-Willi and Angelman syndromes
Chromosome 15q11-13 is enriched for LCRs, providing a mechanism for LCR-mediated
NAHR, and generating a series of recurrent breakpoints along this chromosome. As a result,
interstitial deletion or duplication of this region is common. LCRs can also mediate triplica‐
tions, or, alternatively, the presence of supernumerary isodicentric chromosome 15 (idic(15))
can lead to crossing over between these LCRs, and ultimately, duplication of the region. A
bipartite imprinting center lies at this locus and directs the expression of a number of genes,
resulting in a tissue-specific parent-of-origin effect. As a result, many of the phenotypes
caused by these structural rearrangements also display parent-of-origin effects.
Paternally- or maternally-inherited deletions of human chromosome 15q11-13 result in
Prader-Willi syndrome (PWS) or Angelman syndrome (AS), respectively. Alternatively,
these disorders can be caused by uniparental disomy (UPD), or by balanced translocations
involving this region. Less frequently, imprinting errors, leading to aberrant methylation of
the PWS imprinting center can also cause PWS, and mutations or deletions in the gene
UBE3A can cause AS [11, 59]. The critical region for AS lies 35 kb telomeric to the PWS criti‐
cal region [60]. PWS is characterized by intellectual disability, hypotonia, hyperphagia, obe‐
sity, compulsive and repetitive behaviors, skin picking, tantrums, irritability. In addition,
congenital abnormalities are often observed, including hypogonadism, facial dysmorphism,
and small hands and feet, among others. PWS can also be associated with psychosis, mood
disorders, and ASD [61].
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AS is  a  neurodevelopmental  disorder  that  is  characterized by severe developmental  de‐
lay, intellectual disability, microcephaly, seizures, lack of speech, ataxia, and dysmorphic
facial features [11, 59]. Patients with AS are often described as having happy demeanors,
however hyperactivity, attention deficits, aggression, and repetitive or stereotypic behav‐
iors have also been described [59].  AS has been associated with ASD in several studies,
however,  the  severity  of  the  cognitive  impairments  in  most  patients  with  AS may pre‐
clude an accurate diagnosis [11, 59].
6. Duplication of 15q11-13
It has been estimated that up to ~5% of cases of ASD can be attributed to maternal duplica‐
tion of the genomic region reciprocal to the PWS-AS critical region on chromosome
15q11-13, making it one of the most common chromosomal abnormalities observed in pa‐
tients with ASD [10, 62]. Due to the presence of imprinting at this locus (discussed above),
parent-of-origin effects are seen, and, for interstitial duplications, maternal origin confers an
increased risk for clinical phenotypes. Paternal duplications are much less common, and do
not appear to lead to ASD, as familial cases have been described where a seemingly normal
carrier mother transmits a paternally-derived duplication to their child [63]. However, a
small number of subjects with paternal duplication of 15q11-13 and various clinical pheno‐
types have been described [64]. Phenotypes are dosage-sensitive at this locus; one extra ma‐
ternal copy of 15q11-13 results in partial autism penetrance, while two extra copies (caused
by idic15 or interstitial triplication) result in a much higher penetrance of autism as well as
additional phenotypes that are typically more severe than those seen in patients with dupli‐
cations [62]. In the case of triplications, parent-of-origin effects are no longer observed, and
both paternal and maternal duplications are associated with poor clinical outcomes [65].
This loss of parent-of-origin effects is interesting, and it may be an indication of the underly‐
ing mechanism that may give rise to a predisposition for these phenotypes. Many heteroge‐
neous and complex phenotypes can be associated with increased copy number of this region
including intellectual disability, apraxia, dyslexia, seizures, hypotonia, developmental de‐
lay, gait abnormalities, hyperactivity, schizophrenia, and ASD [66]. Patients with ASD due
to duplication of 15q11-13 also display several stereotypic and repetitive behaviors, includ‐
ing rocking, licking, and hand-flapping, among others, that are often directed towards sen‐
sory stimulation, suggesting that the underlying cause of these phenotypes may be due to a
disregulation of sensory inputs or signaling [63, 64].
Interestingly, recent post-mortem evaluation of the brains of patients harboring maternal
duplication of 15q11-13 suggested that accumulation and deposition of abnormal intracel‐
lular  and extracellular  amyloid β protein (Aβ)  in  the  specific  regions and neuron types
in the brains of patients with maternal duplication of 15q11-13 may underlie or contrib‐
ute to some of the neurobehavioral phenotypes associated with ASD [67]. However, fur‐
ther studies are needed to confirm this hypothesis.  Several animal models for the CNV-
based syndromes associated with chromosome 15q11-13 have been developed to facilitate
research into these disorders.
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7. Modeling 15q11-13 CNVs in mice
The first mouse model for PWS was generated by targeted deletion of part of the imprinting
center on chromosome 15q11-13 [68]. While these mice model several aspects of PWS, in‐
cluding hypersensitivity to sensory input in the form of increased acoustic startle response
and decreased prepulse inhibition, it is not known whether these mice exhibit other autistic-
like behaviors, such as impaired social interactions or altered communication [69]. Further
behavioral characterization is needed to determine whether these mice accurately recapitu‐
late the neurobehavioral phenotypes seen in patients with PWS and/or ASD.
Mouse models for Angelman syndrome were initially generated by disrupting maternal ex‐
pression of Ube3a; these mice exhibit increased anxiety-like behavior that may be due to the
disruption of a glucocorticoid receptor transactivation in the brain [70]. They also display
various motor defects [71], abnormal cerebellum-driven licking behavior [72], sleep disturb‐
ance [73], abnormal EEG patterns, and cognitive defects in the conditioned fear and Morris
water maze tests [74]. However, these mice displayed hypoactivity and normal social seek‐
ing behavior, in contrast to what is seen in human patients with AS and/or ASD [75]. Impor‐
tantly, human patients with mutations in UBE3A typically have a milder phenotype than
those patients harboring interstitial deletions, so this mouse model may not accurately re‐
flect the majority of AS patients, who have a deletion containing this gene, as well as many
other genes at this locus. Indeed, when a larger 1.6 Mb deletion model was generated by
chromosome engineering that encompasses the genomic region from Ube3a to Gabrb3, the
phenotype of these mice was more severe than that of mice with deletion of Ube3a alone
[76]. Similar to Ube3a deficient mice, large deletion mice had significant motor impairment,
anxiety-like behavior, and abnormal EEG, but they also had learning and memory defects
and abnormal communication [76]. These larger deletion mice may be an appropriate model
for CNV-associated ASD, however further investigation into the social neurobehavioral phe‐
notypes is necessary.
Chromosome-engineered mouse models harboring a duplication of 6.3 Mb on mouse chro‐
mosome 7 syntenic to the duplication of human chromosome 15q11-13 associated with ASD
were developed to study the underlying mechanism behind the phenotypes associated with
this CNV in humans [28]. The core features of autism, including abnormal social interac‐
tions, stereotypic or ritualistic behavior, and impaired communication were all evaluated in
this mouse model, and patDp/+, but not matDp/+ mice were determined to have reduced so‐
ciability compared to wild-type mice. Ultrasonic vocalizations were evaluated in pups sepa‐
rated from the dam, and an abnormal USV pattern was observed in patDp/+ but not
matDp/+ mice. Specifically, patDp/+ mice appeared to have delayed development of com‐
munication, they emitted a greater number of USVs, and some pups emitted vocalizations at
abnormally high frequencies (>70 kHz). In order to evaluate communication between older
mice, pairs of mice 7-8 weeks of age were observed in a resident intruder paradigm and the
pattern of USVs was measured during this interaction. Vocal communication between pairs
of pat/Dp/+ mice was significantly reduced compared to the vocalization recorded between
WT pairs, giving further support to the notion that patDp/+ mice have a defect in social
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communication. However, no defects in olfactory communication or function were observed
in these mice. Restricted behaviors and inflexibility were evaluated with a battery of behav‐
ioral tests, including the Morris water maze and the Barnes maze. These tests revealed that
patDp/+ mice do not respond as flexibly to a change in situation as wild-type or matDp/+
mice. No overt defects in learning and memory were observed in either the patDp/+ or
matDp/+ mice by the Morris water maze or conditioned fear test, although patDp/+ mice did
display generalized fear and elevated anxiety-like behavior. The abnormal neurobehavioral
phenotypes observed in this CNV-based model of ASD could not be attributed to gross mor‐
phological or histological changes in the olfactory bulb, cerebral cortex, hippocampus,
amygdala, corpus callosum, or cerebellum. Nor were any abnormalities in the number of
Purkinje cells detected in the cerebellum, suggesting that the underlying pathomechanism
responsible for these phenotypes is likely due to aberrations in molecular pathways that re‐
main to be determined.
The gene Ube3a (also known as E6-AP) codes for E3 ubiquitin-protein ligase, which belongs
to a family of E3 ligase genes that are involved in synaptogenesis and have recently been
linked to the pathogenesis of ASD [62]. Given the known association of the gene UBE3A
with AS and its maternal-specific expression pattern in neurons, a mouse model that overex‐
presses this gene was generated to test the hypothesis that Ube3a is responsible for many of
the phenotypes associated with duplication of 15q11-13 [62]. Transgenic overexpression of
Ube3a via bacterial artificial chromosome (BAC) recombineering in mice resulted in autistic-
like neurobehavioral phenotypes, including defects in communication, abnormal social be‐
havior, and increased repetitive or stereotypic behavior [62]. Similar to the phenomenon
observed in human patients, these effects were also determined to be dosage-sensitive, as
the phenotypes were more penetrant in mice with three-fold overexpression of Ube3a than
in those observed in mice with two-fold overexpression of this gene. Furthermore, it was de‐
termined that glutamatergic synaptic transmission was suppressed, providing a potential
mechanism underlying the neurobehavioral phenotypes.
8. Smith-Magenis and Potocki-Lupski syndromes
Smith-Magenis syndrome (SMS) and Potocki-Lupski syndrome (PTLS) are two prototypical
genomic disorders caused by reciprocal deletion (SMS) or duplication (PTLS) resulting in
gene copy number variation on chromosome 17. SMS results from a de novo, recurrent, 3.7
Mb deletion in 17p11.2 – del(17)(p11.2p11.2) in ~73% of cases, that is a consequence of
NAHR mediated by LCRs flanking the region [77-79]. However, many of the pleiotropic fea‐
tures of SMS appear to result from haploinsufficiency of a single gene lying in the middle of
the SMS critical region, retinoic acid induced 1 (RAI1), as determined by the identification of
non-deletion SMS patients with heterozygous point mutations in RAI1 [80-82]. Patients with
mutations in RAI1 manifest most of the phenotypes observed in subjects with a chromoso‐
mal SMS deletion, demonstrating that the reduced dosage of the RAI1 gene alone may cause
much of the SMS phenotype [81, 83].
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Both SMS and PTLS manifest a broad range of opposing or overlapping phenotypes. SMS is
characterized by multiple congenital anomalies, including otolaryngologic, ophthalmologic,
brain, cardiac, craniofacial, and renal abnormalities, as well as intellectual disability (ID),
brachydactyly, sleep disturbance, hearing impairment, obesity, scoliosis, and other neurobe‐
havioral abnormalities [84, 85]. Specifically, SMS patients display aggressive and self-injuri‐
ous behaviour, including polyembolokoilamania [84], as well as characteristic repetitive
behaviors, including autoamppexation or “self-hugging,” which is an identifying feature of
the disorder [86, 87]. More recently, SMS patients have also been described as meeting the
criteria for autism spectrum disorder (ASD) [88].
The PTLS duplication was the first predicted reciprocal duplication to be described [89].
PTLS was identified and initially defined much later than SMS, ([89] versus Smith et al.
1986); as a result, fewer PTLS patients have been medically examined and fewer studies of
the clinical phenotypes are available in the literature. The clinical features that have been ob‐
served in patients with PTLS are distinct from those seen in SMS [15], although cognitive
and neurobehavioral abnormalities are present in both disorders. PTLS patients lack the
self-injurious behaviors, abnormal facies, and sleep disturbance, as well as some of the con‐
genital anomalies found in most individuals with SMS. The features observed in greater
than 90% of PTLS patients are developmental delay, neurobehavioral abnormalities, lan‐
guage impairment, cognitive impairment, poor feeding, hypotonia, and oropharyngeal dys‐
phasia [15, 90]. When evaluated by objective clinical assessment, the majority of PTLS
patients have autistic features such as decreased eye contact, atypicality, withdrawal, anxi‐
ety, and inattention, meeting criteria for a diagnosis of autistic spectrum disorder (ASD) or
pervasive developmental disorder not otherwise specified, and making ASD the most com‐
mon and consistent feature observed in PTLS. [14].
Most PTLS patients have no distinctive facial abnormalities but they can have a triangular-
shaped face. The other clinical features present in over half of patients include sleep apnea,
abnormal EEG, attention deficit, hypermetropia, and cardiovascular abnormalities [15].
These cardiovascular abnormalities can typically include both structural and conduction de‐
fects, such as atrial or ventricular septal defects, bicuspid aortic valve, dilated aortic root, di‐
lation of the pulmonary annulus, patent foramen ovale, or hypoplastic left heart [15, 91-93].
Upon molecular analysis,  most  [22 of  35]  PTLS patients  included in the first  multidisci‐
plinary  study  were  determined  to  carry  a  common  recurrent  3.7  Mb  duplication  in
17p11.2 mediated by the same proximal and distal SMS-REPs which also mediate the re‐
ciprocal  common  recurrent  SMS  deletion  [15].  Others  have  uncommon  and  sometimes
complex  genomic  rearrangements,  all  of  which  involve  duplication in  17p11.2  [94].  The
smallest PTLS duplication identified to date occurred in a single patient and is 1.3 Mb in
size. This duplicated segment contains 14 genes, including both RAI1, the major contribu‐
ting gene for the reciprocal deletion causing SMS, as well as the steroid-metabolism reg‐
ulating  gene,  SREBP1.  This  patient  demonstrates  all  typical  PTLS  phenotypes  [94].
Whether, or to what extent, PTLS results from RAI1 gene over-dosage still remains to be
elucidated,  although  mouse  studies  (described  below)  have  shown  that  it  is  likely  re‐
sponsible for at least some of the symptoms [95].
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9. RAI1: Retinoic acid induced 1
Spanning over 120 kb, the RAI1 gene consists of six exons, of which the third is the largest,
containing >90% of the coding region [80, 85, 96]. All of the point mutations identified in
SMS patients to date lie within this exon. Most of the mutations are frameshift or nonsense
mutations occurring in a specific heptameric poly C tract hotspot region within RAI1, and
thus likely cause loss-of-function alleles [82, 97].
The RAI1  transcript is 7.6 kb, encoding a 1906-amino acid, ~200 kDa protein with sever‐
al  known domains,  including an extended plant homeodomain (PHD) zinc finger in the
carboxyl-terminus  (residues  1832-1903;  [80]),  a  polymorphic  polyglutamine  (CAG)  tract
in the N-terminus that  is  associated with the severity of  the phenotype and medication
response  in  patients  with  schizophrenia,  as  well  as  the  age-at-onset  of  spino-cerebellar
ataxia  type  2  (SCA2)  [96,  98],  two  polyserine  tracts,  two  transactivation  domains  [99],
and  two  bipartite  nuclear  localization  signals  (NLS).  Importantly,  the  PHD  in  Rai1  is
highly  conserved  in  the  trithorax  family  of  nuclear  proteins  involved  in  transcriptional
regulation  as  well  as  in  the  formation  of  a  chromatin  remodeling  complex,  suggesting
that  Rai1  may  also  function  as  a  transcriptional  regulator  [100].  Further  strengthening
this connection, Rai1 is known to be located in the nucleus and have transactivation ac‐
tivity  [99],  and it  shares  a  similar  genomic  structure  (>50% shared identity  and similar
zinc finger domains)  with another gene,  TCF20,  or  stromelysin1 platelet-derived growth
factor  (PDGF)-responsive  element-binding  protein  (SPBP),  which  is  known  to  act  as  a
nuclear transcriptional cofactor [101].
In the human brain, RAI1 is highly-expressed in the hippocampus and the cerebellar cor‐
tex, and it is globally-upregulated in the occipital, temporal, and parietal lobes according
to expression data from the Allen Brain Atlas (Allen Institute for Brain Science).  In con‐
trast,  it  appears  to  be  down-regulated  in  the  cerebellar  nuclei,  corpus  callosum,  dorsal
thalamus, and frontal lobe, suggesting that its expression is confined to specific brain re‐
gions.  Similar  to  what  is  seen in humans,  Rai1  is  also upregulated in the hippocampus
and cerebellum of adult mice [102].  Rai1  is critical for development, and the majority of
Rai1-/- mouse embryos are resorbed during development by E15.5 [99]. While Rai1 expres‐
sion is certainly necessary early in fetal development, according to expression data from
mouse embryos,  peak Rai1  expression occurs at  E18.5 and persists until  P4 (Allen Brain
Atlas),  indicating that  it  is  also  required for  post-natal  development.  Although the  pre‐
cise function of  RAI1/Rai1  is  not  currently understood,  it  is  known to be part  of  a  dos‐
age-sensitive  pathway  that  most  likely  regulates  neuronal  development  and
organogensis, that, when perturbed, results in many of the phenotypes observed in both
SMS and PTLS.  Importantly,  RAI1  has  been  identified  in  a  reconstructed  human gene-
network  (Prioritizer)  as  an  important  candidate  gene  for  involvement  in  idiopathic  au‐
tism,  suggesting that  this  gene may function in a  common pathway that  may influence
ASD phenotypes in non-syndromic patients as well [103].
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10. Modeling SMS and PTLS in rodents
Several mouse models interrogating the critical region for SMS and PTLS have been generat‐
ed in the past decade in order to have an appropriate animal model system to evaluate the
phenotypes in SMS and PTLS and to further study the molecular mechanism underlying
these disorders. The first of these strains was developed in 2003 using a chromosome-engi‐
neering approach described earlier in this chapter [24]. The resulting mouse models harbour
either a chromosomal duplication (Dp(11)17, modeling PTLS) or deletion (Df(11)17, model‐
ing SMS) of ~2 Mb that is syntenic to the SMS/PTLS critical region. Soon after, several small‐
er deletion strains (~590 kb – 1 Mb) were created using retroviral insertion of loxP sites in ES
cells with one fixed end, with the intent to determine which other genes in the critical region
may contribute to the complex phenotypes in SMS [104, 105]. Once SMS patients with point
mutations in RAI1 were identified, a mouse model harbouring a truncated null allele for
Rai1 was generated via gene targeting to further study the function of this dosage-sensitive
gene and to compare the phenotype of this model with that of the deletion strains [99, 102].
Likewise, a mouse model harbouring the Rai1 transgene (TgRai1), and globally over-ex‐
pressing Rai1 at steady-state levels similar to those seen in Dp(11)17/+ mice, was constructed
to further study the function of this gene in PTLS [106].
Initial studies of Dp(11)17/+ mice determined that they have reduced weight, reduced ab‐
dominal and inguinal fat, and reduced spleen weight [24]. Upon analysis of some of the be‐
havioral traits of these mice, it was determined that they display anxiety-like behaviors,
have reduced maximum startle response during the pre-pulse inhibition test, and defects in
contextual fear conditioning [107], as well as several other abnormal social behaviors, in‐
cluding decreased nesting, abnormal sociability, and dominant behaviour [108]. Further in‐
vestigation into the neurobehavioral abnormalities in these mice found that they also have
decreased preference for social novelty, motor defects, and increased activity levels in the
open field [109]. Many of these behavioral phenotypes are reciprocal or opposing to those
seen in Df(11)17/+ mice, underscoring the dosage-sensitive nature of these disorders [109].
For example, a recent study investigating cerebellum-driven licking behavior in Dp(11)17/+
and Df(11)17/+ mice found that many of the quantitative licking behavior parameters ana‐
lyzed were altered in a directly-opposing manner [110]. Specifically, the interval between
visits to the waterspout, number of licks per visit, and variability in the number of licks per
lick-burst were all altered in duplication and deletion animals in opposite directions com‐
pared to wild-type mice (ex: longer versus shorter intervals, etc).
Recently, an extensive battery of behavioral tests were performed and Dp(11)17/+ mice were
observed to display complex social abnormalities, including defects in social recognition,
dominant and aggressive behavior, as well as abnormal response to social odors [30]. Fur‐
thermore, these mice were shown to have altered communication, anxiety-like behavior, dis‐
ordered circadian rhythm, learning and memory deficits, motor defects, and stereotypic,
repetitive behaviors, confirming that these mice model both the core and associated features
of autism. In addition, rearing these mice in an enriched environment mitigated or rescued
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certain neurobehavioral abnormalities, suggesting a role for gene-environment interactions
in the determination of copy number variation-mediated autism severity [30].
The phenotypic changes observed in Dp(11)17/+ and Df(11017/+ mice are accompanied by
changes in gene expression; on average, transcripts in the critical interval are expressed at
138 + 29% of wild-type levels in Dp(11)17/+ mice, and at 66 + 15% of wild-type levels in
Df(11)17/+ mice [109]. The expression level of these genes can be normalized to roughly that
of wild-type mice by crossing Dp(11)17/+ and Df(11)17/+ mice to create a double heterozy‐
gote carrying two copies of the genes within the critical region in cis, (as opposed to the typi‐
cal trans orientation in wild-type mice). However, the presence of the structural variation
itself affects expression of genes outside the affected interval, resulting in “genome regula‐
tion” that may ultimately contribute to the phenotype. As a result, these double heterozy‐
gous mice display some abnormal behaviors, including elevated activity levels and
decreased preference for social novelty [109].
When Rai1 is over-expressed in mice (Rai1-Tg, modeling PTLS), these mice have growth re‐
tardation, are underweight, display anxiety-like behavior, social dominance, motor abnor‐
malities, and have increased motor activity in juvenile mice. Furthermore, there is a dosage-
dependent exacerbation of this phenotype [106]. These mice also display abnormal maternal
behavior, altered sociability, reduced reproductive fitness, and impaired serotonin metabo‐
lism [111]. Together these results suggest that Rai1-Tg mice display a complex neurobeha‐
vioral and metabolic phenotype similar to that of mice harboring the Dp(11)17 CNV,
suggesting that RAI1 is likely responsible for some, if not many of the phenotypes identified
in PTLS. Further support for this hypothesis is indicated by studies of Dp(11)17/Rai1 double-
heterozygous mice with normalized copy number of Rai1, but increased dosage of the sur‐
rounding interval; this study revealed that normalization of Rai1 copy number was able to
correct weight differences, and at least partially rescue phenotypes on behavioral tests for
locomotor activity, anxiety, and learning and memory [95].
11. Gene-environment interactions
While genetic defects play a part in the etiology of ASD, environmental effects have long
been  thought  to  contribute  to  these  disorders.  For  example,  although  the  majority  of
SMS/PTLS patients present with either deletion or duplication of the same ~3.7 Mb gene-
dense region, there is significant variability in the clinical phenotype [112].  Furthermore,
while  there are some significant  differences in the incidence of  the abnormalities  in pa‐
tients with the common deletion/duplication compared to those patients with smaller or
larger-sized  CNVs,  a  clear  distinction  between  these  sub-groups  of  patients  cannot  be
made; many of these phenotypes are therefore likely strongly influenced by genetic back‐
ground  as  well  as  environmental  effects  [83,  94].  While  gene-environment  interactions
may potentially explain the source of the variability seen in these syndromes, investiga‐
tion into  the  specific  environmental  factors  that  may affect  outcomes for  these  genomic
disorders has yet to be undertaken.
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Chromosome-engineered mouse models for ASD are ideal for the study of complex disease,
as they are mechanistically similar to human patients (targeted duplication/deletion synten‐
ic to human critical interval), they are polygenic (numerous genes are affected), the observed
phenotypes equate with common, clinically described features (neurobehavioral pheno‐
types, sleep disorder, etc), and they can be influenced by environmental factors. In addition,
autism is known to be highly variable, and it is suspected to be dependent on both genetic
and environmental factors, such as low birth weight and gestational age, prenatal exposure
to various agents, parental age at birth, diet, infection, xenobiotic and pesticide exposure,
among others [113]. Many of these environmental insults are amenable to study using
mouse models, as the interaction of these environmental factors with CNVs can be directly
tested in congenic mouse models to control for the effects of genetic background.
Molecular analysis of these mouse models, as well as patient samples, can also be utilized to
dissect the role of specific genes or CNVs responsible for the susceptibility to the influence
of environmental factors in these autism-related syndromes. Most importantly, the results of
these types of studies can provide useful insights as to how genes/CNVs can interact with
environmental factors in the context of complex human diseases; this may lead to strategies
to alleviate symptoms of not only rare genomic disorders, but also more common idiopathic
forms of autism or ASD. Furthermore, these models represent an important resource for fu‐
ture studies of the pathomechanisms underlying ASD, as well as potential treatments for
ASD. They may also foster further investigation into the genomic basis of autism and com‐
plex behavior, as well the underlying genetic mechanisms leading to these pathogenic
CNVs. In studying CNV-based models for complex genomic disorders and ASD, we have
come to realize that the ideal animal models of ASD should not only phenocopy relevant
human symptoms, but the phenotypes should also be based on similar underlying physio‐
logical and genetic mechanisms.
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